In the present study, we employed scRNA-seq of PBMCs from individuals with new-onset NS to investigate the mechanistic links between IFN activation, antibody production and NS pathogenesis to identify potential therapeutic targets. The gene discussed is IFNA1; the disease is Netherton syndrome.